Hanx Biopharmaceuticals (Wuhan) Co., Ltd. reported that on 13 May 2026 it bought back 26,400 H shares on the Hong Kong Stock Exchange, paying a volume-weighted average of HKD 30.98 per share within a price range of HKD 30.00–32.50. The aggregate consideration totalled HKD 0.82 million.

Post-transaction, issued shares (excluding treasury shares) decreased by 0.019% to 135.62 million, while total issued shares remained unchanged at 136.22 million. Treasury shares rose to 598,600 units.

The buyback was executed under the mandate approved on 12 February 2026, which authorises the repurchase of up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 598,600 shares, equivalent to 0.44% of the issued share base on the mandate date. A moratorium on new share issues or treasury-share sales is in force until 12 June 2026.

The company confirmed that the repurchase complied with all applicable Hong Kong listing rules and regulatory requirements.